JAK-话题@MedSci

#JAK#

115篇内容 | 2655人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738029, encodeId=bc1d1e3802909, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号, objectType=article, longId=190457, objectId=fbcc19045e07, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbcc19045e07, replyNumber=0, likeNumber=80, createdTime=2020-11-15, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbcc19045e07, moduleTitle=礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbcc19045e07)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738043, encodeId=fbd81e380436b, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, objectType=article, longId=196190, objectId=6f67196190f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f67196190f1, replyNumber=0, likeNumber=86, createdTime=2020-12-08, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f67196190f1, moduleTitle=艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f67196190f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738041, encodeId=602e1e38041cc, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=55, createdTime=2020-09-12, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738042, encodeId=36b71e3804271, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Blood：JAK/STAT抑制增强CD8 T细胞对地塞米松诱导的细胞凋亡的敏感性, objectType=article, longId=195861, objectId=a97019586128, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a97019586128, replyNumber=0, likeNumber=34, createdTime=2020-07-19, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a97019586128, moduleTitle=Blood：JAK/STAT抑制增强CD8 T细胞对地塞米松诱导的细胞凋亡的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a97019586128)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738047, encodeId=26b91e38047b9, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Immunity：从复杂的自体炎症性疾病揭示JAK1激酶的基本功能, objectType=article, longId=199641, objectId=5942199641a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5942199641a8, replyNumber=0, likeNumber=58, createdTime=2020-11-26, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5942199641a8, moduleTitle=Immunity：从复杂的自体炎症性疾病揭示JAK1激酶的基本功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5942199641a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738028, encodeId=0c6f1e38028a9, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=III期JADE Compare试验：JAK1抑制剂abrocitinib治疗特应性皮炎取得积极结果, objectType=article, longId=190430, objectId=bffb1904303e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bffb1904303e, replyNumber=0, likeNumber=79, createdTime=2020-04-23, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bffb1904303e, moduleTitle=III期JADE Compare试验：JAK1抑制剂abrocitinib治疗特应性皮炎取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bffb1904303e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738021, encodeId=122b1e38021e0, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Incyte宣布JAK1抑制剂Itacitinib在移植物抗宿主病患者中的3期研究结果, objectType=article, longId=185644, objectId=baa51856448b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=baa51856448b, replyNumber=0, likeNumber=69, createdTime=2020-10-08, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=baa51856448b, moduleTitle=Incyte宣布JAK1抑制剂Itacitinib在移植物抗宿主病患者中的3期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=baa51856448b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738020, encodeId=be511e380209a, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Blood：JAK2ex13InDel驱动成瘤转化，与慢性嗜酸性粒细胞白血病和真性红细胞增多症有关, objectType=article, longId=185564, objectId=35fa1855647f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35fa1855647f, replyNumber=0, likeNumber=110, createdTime=2020-12-01, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35fa1855647f, moduleTitle=Blood：JAK2ex13InDel驱动成瘤转化，与慢性嗜酸性粒细胞白血病和真性红细胞增多症有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35fa1855647f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738033, encodeId=74991e3803362, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=综述：JAK抑制剂治疗银屑病, objectType=article, longId=192566, objectId=8c161925667d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c161925667d, replyNumber=0, likeNumber=73, createdTime=2020-12-12, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c161925667d, moduleTitle=综述：JAK抑制剂治疗银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c161925667d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738026, encodeId=8fba1e38026fa, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=NEJM：JAK抑制剂ruxolitinib治疗遗传性USP18缺乏症, objectType=article, longId=188465, objectId=e9c4188465bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9c4188465bc, replyNumber=0, likeNumber=86, createdTime=2021-01-05, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9c4188465bc, moduleTitle=NEJM：JAK抑制剂ruxolitinib治疗遗传性USP18缺乏症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9c4188465bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738038, encodeId=9d5c1e38038d6, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=JAK1抑制剂新突破！溃疡性结肠炎新药filgotinib达到试验主要终点, objectType=article, longId=194505, objectId=e08f19450510, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e08f19450510, replyNumber=0, likeNumber=66, createdTime=2020-07-14, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e08f19450510, moduleTitle=JAK1抑制剂新突破！溃疡性结肠炎新药filgotinib达到试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e08f19450510)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738037, encodeId=14e41e38037a6, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Gastroenterology：警惕JAK抑制剂治疗导致患者带状疱疹风险增加, objectType=article, longId=194409, objectId=236b194409a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=236b194409a2, replyNumber=0, likeNumber=74, createdTime=2020-08-21, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=236b194409a2, moduleTitle=Gastroenterology：警惕JAK抑制剂治疗导致患者带状疱疹风险增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=236b194409a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738039, encodeId=c6ca1e3803937, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=AbbVie向美国和欧洲药品管理局提交营销申请，将JAK抑制剂Rinvoq用于治疗银屑病关节炎, objectType=article, longId=195324, objectId=869819532415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=869819532415, replyNumber=0, likeNumber=84, createdTime=2020-12-14, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=869819532415, moduleTitle=AbbVie向美国和欧洲药品管理局提交营销申请，将JAK抑制剂Rinvoq用于治疗银屑病关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=869819532415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738017, encodeId=0fe11e38017ff, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果, objectType=article, longId=181538, objectId=4e6d181538d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e6d181538d7, replyNumber=0, likeNumber=74, createdTime=2020-04-06, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e6d181538d7, moduleTitle=辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e6d181538d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738011, encodeId=40201e3801153, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=5.9万美元/年！艾伯维官宣JAK抑制剂Rinvoq定价，8月底登陆美国！, objectType=article, longId=178087, objectId=e5861e8087e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5861e8087e1, replyNumber=0, likeNumber=92, createdTime=2020-06-13, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5861e8087e1, moduleTitle=5.9万美元/年！艾伯维官宣JAK抑制剂Rinvoq定价，8月底登陆美国！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5861e8087e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738031, encodeId=0e2b1e3803150, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验, objectType=article, longId=192249, objectId=f473192249cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f473192249cd, replyNumber=0, likeNumber=91, createdTime=2021-01-02, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f473192249cd, moduleTitle=JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f473192249cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738014, encodeId=892f1e380147c, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Blood：JAK2突变型造血细胞的代谢变化可作为MPN的治疗靶点, objectType=article, longId=179590, objectId=f88b1e959038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f88b1e959038, replyNumber=0, likeNumber=65, createdTime=2020-05-01, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f88b1e959038, moduleTitle=Blood：JAK2突变型造血细胞的代谢变化可作为MPN的治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f88b1e959038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738018, encodeId=bdd41e38018cb, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功, objectType=article, longId=184287, objectId=1a1218428e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a1218428e0d, replyNumber=0, likeNumber=86, createdTime=2020-04-13, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a1218428e0d, moduleTitle=吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a1218428e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738036, encodeId=2f961e380369a, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性, objectType=article, longId=194372, objectId=d9c31943e212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c31943e212, replyNumber=0, likeNumber=64, createdTime=2020-09-09, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c31943e212, moduleTitle=Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c31943e212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738025, encodeId=227a1e3802586, content=<a href='/topic/show?id=0abd10215e0' target=_blank style='color:#2F92EE;'>#JAK#</a>, objectTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, objectType=article, longId=187166, objectId=2f3218e16658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f3218e16658, replyNumber=0, likeNumber=79, createdTime=2020-08-31, rootId=0, userName=肉我只吃一口, userId=6e8634348903, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f3218e16658, moduleTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f3218e16658)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

JAK

2020-05-29

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

礼来的JAK抑制剂Baricitinib治疗斑秃，获得FDA授予突破性疗法称号

2020-11-15

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

艾伯维的JAK抑制剂Rinvoq，III期临床显示出治疗特应性皮炎的潜力

2020-12-08

heli0118 (审核中...)

前往app查看评论内容

#JAK#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2020-09-12

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Blood：JAK/STAT抑制增强CD8 T细胞对地塞米松诱导的细胞凋亡的敏感性

2020-07-19

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Immunity：从复杂的自体炎症性疾病揭示JAK1激酶的基本功能

2020-11-26

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

III期JADE Compare试验：JAK1抑制剂abrocitinib治疗特应性皮炎取得积极结果

2020-04-23

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Incyte宣布JAK1抑制剂Itacitinib在移植物抗宿主病患者中的3期研究结果

2020-10-08

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Blood：JAK2ex13InDel驱动成瘤转化，与慢性嗜酸性粒细胞白血病和真性红细胞增多症有关

2020-12-01

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

综述：JAK抑制剂治疗银屑病

2020-12-12

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

NEJM：JAK抑制剂ruxolitinib治疗遗传性USP18缺乏症

2021-01-05

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

JAK1抑制剂新突破！溃疡性结肠炎新药filgotinib达到试验主要终点

2020-07-14

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Gastroenterology：警惕JAK抑制剂治疗导致患者带状疱疹风险增加

2020-08-21

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

AbbVie向美国和欧洲药品管理局提交营销申请，将JAK抑制剂Rinvoq用于治疗银屑病关节炎

2020-12-14

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

辉瑞宣布其口服JAK1抑制剂阿布西替尼治疗特应性皮炎的阳性III期临床结果

2020-04-06

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

5.9万美元/年！艾伯维官宣JAK抑制剂Rinvoq定价，8月底登陆美国！

2020-06-13

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

JAK抑制剂Olumiant和抗血管生成素-2单抗LY3127804将用于新冠病毒COVID-19患者临床试验

2021-01-02

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Blood：JAK2突变型造血细胞的代谢变化可作为MPN的治疗靶点

2020-05-01

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功

2020-04-13

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性

2020-09-09

肉我只吃一口 (审核中...)

前往app查看评论内容

#JAK#

礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果

2020-08-31

科室
- - 订阅+
  - 更多科室
工具
服务